ekonominyheter

TranslateRSSMobil
Gilead Sciences, Inc. Takes Aim at Bristol-Myers Squibb

Gilead Sciences, Inc. Takes Aim at Bristol-Myers Squibb

Fool.com 29/9 09:35

Gilead Sciences has filed for approval of its next generation hepatitis C drug in Japan in a move that will challenge Bristol-Myers first to market advantage.

Till artikeln

Ekonomi Nyheter .se - Innehåll

 

 

 

 

DMCA.com Protection Status